10-Q: OmniAb Reports Third Quarter 2024 Results: Revenue Declines Amidst Shifting Milestones

OmniAb's third quarter 2024 results show a decrease in revenue compared to the same period last year, primarily due to lower milestone and service revenue.

Summary

• OmniAb's third quarter 2024 revenue totaled $4.17 million, a decrease of 24% compared to $5.48 million in the third quarter of 2023.
• The decline in revenue was primarily driven by a decrease in license and milestone revenue, which fell to $1.38 million from $2.01 million, and a decrease in service revenue, which fell to $2.48 million from $3.02 million.
• Royalty revenue also decreased to $0.32 million from $0.45 million.
• The company reported a net loss of $16.37 million, or $0.16 per share, compared to a net loss of $15.74 million, or $0.16 per share, in the same quarter of the previous year.
• For the nine months ended September 30, 2024, total revenue was $15.59 million, a 47% decrease from $29.34 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $48.97 million, or $0.48 per share, compared to a net loss of $36.57 million, or $0.37 per share, for the same period in 2023.
• The company's cash, cash equivalents, and short-term investments totaled $59.4 million as of September 30, 2024.
• OmniAb believes its current cash position will support operations for at least the next 12 months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant revenue declines and increased losses, offset by a strong partner base and sufficient cash for the next 12 months. The overall sentiment is negative due to the financial performance, but there are some positive indicators for the future.

Positives

• The company has 86 active partners, indicating a strong market presence.
• There are 352 active programs utilizing OmniAb's technology, suggesting continued demand.
• The company has 33 active clinical programs and 3 approved products, indicating potential for future revenue.
• Cash, cash equivalents, and short-term investments are sufficient to support operations for at least the next 12 months.
• The company has an ATM offering program in place to raise additional capital if needed.

Negatives

• Total revenue decreased by 24% in the third quarter and 47% for the nine months ended September 30, 2024, compared to the same periods in 2023.
• License and milestone revenue decreased significantly, indicating a potential slowdown in new partnerships or milestone achievements.
• Service revenue also declined, suggesting a decrease in research program activity.
• Royalty revenue decreased, indicating lower sales from partners' products.
• The net loss increased to $16.37 million in the third quarter and $48.97 million for the first nine months of 2024.
• The company experienced a $1.2 million impairment of certain intangible assets.

Risks

• The company's ability to continue operations is dependent on generating cash flows and potentially obtaining additional capital.
• The company is subject to risks related to the success of its partners' programs, which it does not control.
• The timing and likelihood of reaching marketing authorization in drug discovery and development are uncertain.
• The company's revenue is dependent on milestone payments and royalties, which are subject to significant uncertainty.
• The company may need to raise additional capital in the future, which may not be available on acceptable terms or at all.
• The company's warrants are currently out of the money, limiting potential cash proceeds from their exercise.

Future Outlook

The company believes its existing cash, cash equivalents, and short-term investments, along with expected cash from operations, will support operations for at least the next 12 months. The company may consider raising additional capital in the future to expand its business, pursue strategic investments, or take advantage of favorable market conditions.

Management Comments

• The company believes the long-term value of its business will be driven by royalties.
• The company believes its revenue will be materially driven by milestones in the shorter term, and by royalties in the longer term, from its partnered programs.

Industry Context

OmniAb operates in the competitive biotechnology sector, licensing its technology to pharmaceutical and biotech companies. The decrease in revenue may reflect broader industry trends or challenges in securing new partnerships and achieving milestones. The company's focus on antibody discovery and next-generation therapeutics positions it in a growing market, but success depends on the progress of its partners' programs.

Comparison to Industry Standards

• The decrease in revenue is concerning compared to other biotechnology companies that are experiencing growth in the same period.
• The company's reliance on milestone payments and royalties is typical in the industry, but the significant decrease in these revenue streams is a negative signal.
• The company's cash position is adequate for the next 12 months, but it may need to raise additional capital if it does not achieve revenue growth.
• The number of active partners and programs is a positive sign, but the company needs to convert these into revenue.
• Compared to companies like Ligand, from which it was spun out, OmniAb is experiencing a more challenging period in terms of revenue growth.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and the increased net loss.
• Employees may be affected by any potential cost-cutting measures.
• Partners may be impacted by the company's financial performance and any changes in its strategy.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on expanding its partnerships and advancing its partners' programs.
• The company will monitor its cash position and may raise additional capital if needed.
• The company will continue to develop its technology platform and explore new opportunities.

Key Dates

Keywords

biotechnology, antibody discovery, therapeutic development, license revenue, milestone revenue, royalty revenue, clinical programs, transgenic animals, drug discovery, OmniAb